« Return to News | Clinical Intelligence

Cellectis, Lonza reach milestone with CHO-K1SV GS

Friday, July 22, 2011 10:14 AM

Cellectis bioresearch and Lonza have reached a significant milestone in the development of a newly bioengineered cell line.

Using their proprietary meganuclease technology, Cellectis bioresearch successfully managed to deactivate ("knock-out") the cell-based glutamine synthetase (GS) in CHO-K1SV, Lonza's proprietary host cell line. This achievement comes as part of an overall strategic plan to further advance the GS Gene Expression System offering and is expected to contribute to shortened development timelines critical for the early phases of bioproduction.

Lonza's proprietary technology, the GS Gene Expression System, uses selection via glutamine metabolism to rapidly generate high-yielding and stable recombinant cell lines. Hundreds of cell lines using the GS System have already been created to generate therapeutic proteins for clinical trials and in-market supply. Removal of the cell-based GS activity will enable further improvements to be made to the selection process for creating highly productive recombinant cell lines.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.